Emerging Role of Nuclear Receptors for the Treatment of NAFLD and NASH

Authors

Ryan D. Welch, Blackburn College
Cyrielle Billon, Washington University in St. Louis
McKenna Losby, Washington University School of Medicine in St. Louis
Gonzalo Bedia‐diaz, Washington University in St. Louis
Yuanying Fang, Washington University in St. Louis
Amer Avdagic, Washington University in St. Louis
Bahaa Elgendy, Washington University in St. Louis
Thomas P. Burris, University of Florida
Kristine Griffett, Auburn University College of Veterinary Medicine

Document Type

Article

Publication Title

Metabolites

Abstract

Non‐alcoholic fatty liver (NAFLD) over the past years has become a metabolic pandemic linked to a collection of metabolic diseases. The nuclear receptors ERRs, REV‐ERBs, RORs, FXR, PPARs, and LXR are master regulators of metabolism and liver physiology. The characterization of these nuclear receptors and their biology has promoted the development of synthetic ligands. The possibility of targeting these receptors to treat NAFLD is promising, as several compounds includ-ing Cilofexor, thiazolidinediones, and Saroglitazar are currently undergoing clinical trials. This review focuses on the latest development of the pharmacology of these metabolic nuclear receptors and how they may be utilized to treat NAFLD and subsequent comorbidities.

DOI

10.3390/metabo12030238

Publication Date

3-1-2022

Recommended Citation

Welch, Ryan D.; Billon, Cyrielle; Losby, McKenna; Bedia‐diaz, Gonzalo; Fang, Yuanying; Avdagic, Amer; Elgendy, Bahaa; Burris, Thomas P.; and Griffett, Kristine, "Emerging Role of Nuclear Receptors for the Treatment of NAFLD and NASH" (2022). Pharmaceutical and Administrative Sciences Faculty Publications. 49. https://doi.org/10.3390/metabo12030238
https://collections.uhsp.edu/pharm-admin-sciences_pubs/49